Elicio Therapeutics, Inc. (ELTX) Discusses Camupepimut Development in Neoadjuvant and Metastatic Pancreatic Cancer Transcript
HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Lowers Price Target to $21
Elicio Therapeutics: Q3 Earnings Snapshot
Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Elicio Therapeutics Q3 EPS $(0.30) Beats $(0.43) Estimate
Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC
Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting
Elicio Therapeutics To Demonstrate Data Of Two Poster Presentations For Its Phase 2 AMPLIFY-7P Trial Of Camupepimut , Expanded Antigen-Agnostic Intratumoral Application Of AMP-Adjuvant Platform At Society For Immunotherapy Of Cancer's Annual Meeting
Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine
Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results At ESMO Congress 2026; Multiple Pre-Specified Subgroup Analyses Favored Camupepimut, Including Patients With And Without Detectable Baseline ctDNA; Encouraging Disease-Free Survival Outcomes Were Observed In Both ctDNA-Negative And ctDNA-Positive Patients
Elicio Therapeutics Presents Data From Its Phase 2 AMPLIFY-7P Trial Of Camupepimut At European Society For Medical Oncology Congress 2026
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
B. Riley Securities Maintains Buy on Elicio Therapeutics, Lowers Price Target to $8
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $23 Price Target
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Elicio Therapeutics Q2 EPS $(0.43) Beats $(0.54) Estimate
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
Another Blow For ELTX? Elicio Raises Fresh Capital Weeks After Trial Disappointment
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.